Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)

Apr 10th, 2024

Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics.

Investor Webinar Notification – Starpharma x Medicxi Partnership (ASX Announcement)

Apr 8th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Tuesday, 9 April 2024.

Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)

Apr 8th, 2024

Medicxi to invest up to USD $25M into newly established entity, Petalion Therapeutics, led by highly experienced pharmaceutical executive Dr Mehdi Shahidi

Half Yearly Report and Accounts (ASX Announcement)

Feb 28th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Interim Report and Half-Year Financial Results for the period ended 31 December 2023 (H1 FY24).

VivaGel® BV US FDA Appeal Outcome (ASX Announcement)

Feb 19th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel^® BV. The FDA has maintained its position that they require additional clinical efficacy data to be generated for the regulatory approval of VivaGel^® BV for bacterial vaginosis (BV) in the US. The formal dispute resolution process involved multiple submissions, meetings, detailed analyses, and the preparation of regulatory precedents relating to recent product approvals. Starpharma was supported through this process by highly experienced regulatory advisers, key opinion leaders, and biostatistical and legal advisers, including several who were ex-FDA.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Jan 31st, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2023 (Q2 FY24). Starpharma’s closing cash balance as at 31 December 2023 was $32.1 million.

Viraleze shows antiviral efficacy in COVID-19 patients (ASX Announcement)

Jan 29th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the results of the post-market clinical study of Viraleze™ nasal spray in participants with COVID-19, demonstrating that Viraleze™ reduced SARS-CoV-2 viral load in the nose, increased the rate of virus clearance from the nose, improved key symptoms of COVID-19, including loss of smell (anosmia), and was well-tolerated.

VivaGel® BV sales and distribution agreement – MENA region (ASX Announcement)

Jan 22nd, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it has signed a sales and distribution agreement for its VivaGel^® BV product with ITROM Pharmaceutical Group, covering 13 countries across the Middle East and North Africa (MENA) region. In this region, the prevalence of bacterial vaginosis among a female population of 238 million is 25%, indicating a high need for new effective therapeutic approaches and a significant opportunity for VivaGel^® BV.

DEP® cabazitaxel data presentation at ASCO GI cancer meeting (ASX Announcement)

Jan 19th, 2024

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the presentation of the positive results from its Phase 2 clinical trial of DEP^® cabazitaxel at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, which is being held from 18 to 20 January 2024 in San Francisco, US. ASCO is the world's leading professional organisation for physicians and oncology professionals. The ASCO GI Cancers Symposium is the only global meeting of its kind focusing on the latest innovative science and clinical developments in GI cancer treatment, research, and care. It brings together oncology thought leaders, practising clinicians, novel drug developers, and GI specialists from around the world.

Positive DEP® docetaxel Phase 2 results (ASX Announcement)

Dec 19th, 2023

Starpharma today announces positive final results from the completed Phase 2 clinical program of DEP^® docetaxel. The clinical program included a monotherapy arm and two combination arms. The Phase 2 trial objectives were met, with endpoints demonstrating encouraging anti-tumour activity of DEP^® docetaxel when administered as a monotherapy or in combination with other anti-cancer agents, nintedanib or gemcitabine, in multiple advanced, metastatic cancers, including pancreatic, gastro-oesophageal, non-small cell lung cancer (NSCLC) and cholangiocarcinoma. 

Starpharma to present DEP® at Radiopharmaceuticals Summit (ASX Announcement)

Dec 6th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces it is presenting at the Targeted Radiopharmaceuticals Summit Europe, having been invited to present at the specialist radiotheranostics conference being held in Berlin, Germany, from 5 to 7 December 2023.

AGM Chairman's address and CEO's presentation (ASX Announcement)

Nov 30th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) releases the attached Chairman’s address and the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited, to be held today at 2:00 pm (Melbourne time).

Starpharma announces new CEO, Ms Cheryl Maley (ASX Announcement)

Nov 10th, 2023

Starpharma is today pleased to announce the appointment of Ms Cheryl Maley as Chief Executive Officer (CEO) and Managing Director of Starpharma effective 8 January 2024.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Oct 31st, 2023

Starpharma today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2023 (Q1 FY24).

SPL to present DEP radiotheranostics at Wilsons Conference (ASX Announcement)

Oct 26th, 2023

Starpharma today announces that it will present at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.

Starpharma receives $7.2 million R&D Tax Incentive refund (ASX Announcement)

Oct 23rd, 2023

Starpharma today announces it has received a $7.2 million research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.

Positive DEP® Cabazitaxel Phase 2 Results in Multiple Cancers (ASX Announcement)

Oct 18th, 2023

Starpharma today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP^® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP^® cabazitaxel in advanced, metastatic castrate-resistant prostate cancer (mCRPC), as well as other difficult-to-treat cancers, including platinum-resistant ovarian cancer and gastro-oesophageal cancers.

DEP® irinotecan IO/PARP combination data presented at AACR (ASX Announcement)

Oct 16th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan combination data poster, showcasing the recently announced1 data for DEP® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models.

DEP® irinotecan clinical data presented at AACR meeting (ASX Announcement)

Oct 16th, 2023

Starpharma today provides a copy of the DEP® irinotecan clinical poster, highlighting the recently announced1 positive interim clinical data from Starpharma’s Phase 1/2 clinical trial, which demonstrated durable anti-tumour responses in advanced colorectal cancer (CRC) and platinum-resistant/refractory ovarian cancer.

DEP® theranostic presented at international oncology meeting (ASX Announcement)

Oct 16th, 2023

Starpharma today provides a copy of the poster that showcases the results from a study of DEP® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model.

Date of Starpharma’s Annual General Meeting 2023 (ASX Announcement)

Oct 2nd, 2023

Starpharma today announces, in accordance with ASX Listing Rule 3.13.1, that its 2023 Annual General Meeting (AGM) will be held at 2:00 p.m. (Melbourne time) on Wednesday, 29 November 2023.

DEP® irinotecan combination data to be presented at international oncology conference (ASX Announcement)

Sep 27th, 2023

Starpharma today announces the presentation of data that demonstrate the benefits of combining DEP^® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.

VIRALEZE™ UK COVID-19 Clinical Study Completes Recruitment (ASX Announcement)

Sep 25th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed recruitment for the post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE™, in patients with COVID-19 in the UK. Recruitment proceeded rapidly and the study successfully enrolled ~200 patients with laboratory-confirmed COVID-19.

Positive DEP® irinotecan clinical results to be presented at international oncology conference (ASX Announcement)

Sep 13th, 2023

Starpharma today announces positive interim results from its Phase 1/2 clinical trial of DEP^® irinotecan will be presented at the upcoming American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Boston, US, from 11 to 15 October 2023.

Change of Company Secretary (ASX Announcement)

Aug 28th, 2023

Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.

Appendix 4G – Corporate Governance Statement (ASX Announcement)

Aug 24th, 2023

Starpharma today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

Starpharma annual report and full-year financial results (ASX Announcement)

Aug 24th, 2023

Starpharma today releases its annual report and full-year financial results for the year ended 30 June 2023.

Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV (ASX Announcement)

Aug 14th, 2023

Starpharma today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel^® BV product.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Jul 31st, 2023

Starpharma today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2023 (Q4 FY23).

Partnered program update (ASX Announcement)

Jul 31st, 2023

Following communication from AstraZeneca on Friday, 28 July 2023, and the subsequent release of AstraZeneca’s H1 and Q2 2023 results announcement that day, Starpharma (ASX: SPL, OTCQX: SPHRY) reports that AstraZeneca has made the decision to discontinue the development of AZD0466, after an internal review, prompted by a small number of asymptomatic adverse events (AEs) that were unrelated to Starpharma’s dendrimer drug delivery technology.

Starpharma partners with UQ to advance DEP® radio pipeline (ASX Announcement)

Jul 26th, 2023

Starpharma today announces it has entered a new partnership with The University of Queensland’s (UQ’s) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub), which has been awarded $4.8 million from the Australian Government’s Australian Research Council (ARC).

DEP® HER2-radiodiagnostic shows imaging benefits (ASX Announcement)

Jul 21st, 2023

Starpharma today announces that DEP^® HER2-zirconium, its HER2-targeted radiodiagnostic candidate, has demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER+ breast cancer model.

Clinical trial update (ASX Announcement)

Jun 27th, 2023

A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419).

Mundipharma to be acquired by iNova (News)

Jun 27th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) notes a press release distributed overnight by iNova Pharmaceuticals (iNova) announcing the acquisition of a consumer health product portfolio from Mundipharma International, one of Starpharma’s VivaGel^® BV product partners.

Life Sciences Investor Presentation (ASX Announcement)

Jun 23rd, 2023

Further to yesterday’s announcement, Starpharma (ASX: SPL, OTCQX: SPHRY) provides a copy of the investor presentation that was aired during the OTCQX’s Virtual Life Sciences Investor Forum on Thursday, 22 June 2023 at 10:00 am EDT (Friday, 23 June 2023, at 12:00 am AEST).

Starpharma to present at Life Sciences Investor Forum (ASX Announcement)

Jun 22nd, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that an investor presentation by Chief Executive Officer, Dr Jackie Fairley, will be broadcast at 10:00 am EDT on Thursday, 22 June 2023 (12:00 am AEST on Friday, 23 June 2023), as part of the OTCQX’s Virtual Life Sciences Investor Forum.

AZD0466 clinical data presented by AstraZeneca at EHA Congress (ASX Announcement)

Jun 14th, 2023

Starpharma today announces the presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress (EHA Congress), which was held from 8 - 11 June 2023.

Starpharma CEO to retire in 2024 (ASX Announcement)

Jun 9th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) wishes to advise that following her significant tenure as the Company’s Chief Executive Officer (CEO), Dr Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.

VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement)

Jun 5th, 2023

Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Apr 28th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.

HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)

Apr 26th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has developed a HER2-targeted DEP^® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu^®[1].

AZD0466 active in small cell lung cancer patient models (ASX Announcement)

Apr 20th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.

DEP® cabazitaxel Phase 2 clinical trial completes enrolment and treatment (ASX Announcement)

Apr 17th, 2023

Starpharma today announces that it has completed enrolment and treatment of patients for the Phase 2 clinical trial of its investigational anticancer product DEP^® cabazitaxel. Encouraging efficacy signals, including significant tumour shrinkage and substantial tumour biomarker reductions, have been observed in multiple cancer types, including prostate cancer, ovarian cancer, gastro-oesophageal cancer, cholangiocarcinoma and head and neck cancer, following treatment with DEP^® cabazitaxel.

Commencement of CFO and Company Secretary (ASX Announcement)

Apr 3rd, 2023

Melbourne, Australia; 3 April 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that, further to the announcement on 3 March 2023, Mr Justin Cahill commences in the role of Chief Financial Officer (CFO) and Company Secretary today. 

Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)

Mar 22nd, 2023

Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.

CFO and Company Secretary Appointment (ASX Announcement)

Mar 3rd, 2023

Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.

Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)

Feb 28th, 2023

Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).

Dr Russell Basser appointed as non-executive director (ASX Announcement)

Jan 31st, 2023

The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.

Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.

Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Jan 30th, 2023

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2022 (Q2 FY23).

Starpharma’s cash balance as at 31 December 2022 was $44.0 million, with a positive net operating cash flow of $2.2 million for the quarter. Total receipts of $8.1 million in the quarter include $7.1 million received from the Australian Government under its R&D tax incentive scheme and receipts from customers of $1.0 million. Customer receipts, including from sales of VIRALEZE™ and VivaGel^® BV, were up 59% from the previous quarter (Q1 FY23: $0.6 million).

Starpharma receives $7.1M R&D tax incentive refund (ASX announcement)

Dec 23rd, 2022

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.